WO2012050975A3 - Nouvelles molécules d'arn circulaire de mammifère et utilisations associées - Google Patents

Nouvelles molécules d'arn circulaire de mammifère et utilisations associées Download PDF

Info

Publication number
WO2012050975A3
WO2012050975A3 PCT/US2011/054004 US2011054004W WO2012050975A3 WO 2012050975 A3 WO2012050975 A3 WO 2012050975A3 US 2011054004 W US2011054004 W US 2011054004W WO 2012050975 A3 WO2012050975 A3 WO 2012050975A3
Authority
WO
WIPO (PCT)
Prior art keywords
rna molecules
mammalian rna
novel circular
methods
anril
Prior art date
Application number
PCT/US2011/054004
Other languages
English (en)
Other versions
WO2012050975A2 (fr
Inventor
Norman E. Sharpless
Zefeng Wang
Christin E. Burd
William R. Jeck
Alex P. Siebold
Original Assignee
The University Of North Carolina At Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of North Carolina At Chapel Hill filed Critical The University Of North Carolina At Chapel Hill
Publication of WO2012050975A2 publication Critical patent/WO2012050975A2/fr
Publication of WO2012050975A3 publication Critical patent/WO2012050975A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des acides nucléiques isolés et purifiés codant pour un ARN circulaire comprenant un ou plusieurs exons ANRIL, des procédés de détection de ces acides nucléiques, et leurs utilisations. L'invention concerne des procédés de détection de troubles associés à ANRIL tels que l'athérosclérose, des kits associés, et des procédés de criblage de composés destinés à prévenir ou traiter ces troubles.
PCT/US2011/054004 2010-09-29 2011-09-29 Nouvelles molécules d'arn circulaire de mammifère et utilisations associées WO2012050975A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38791810P 2010-09-29 2010-09-29
US61/387,918 2010-09-29

Publications (2)

Publication Number Publication Date
WO2012050975A2 WO2012050975A2 (fr) 2012-04-19
WO2012050975A3 true WO2012050975A3 (fr) 2012-07-05

Family

ID=45938895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/054004 WO2012050975A2 (fr) 2010-09-29 2011-09-29 Nouvelles molécules d'arn circulaire de mammifère et utilisations associées

Country Status (1)

Country Link
WO (1) WO2012050975A2 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578205A1 (fr) 2010-08-06 2019-12-11 ModernaTX, Inc. Compositions pharmaceutiques a base d'acides nucléiques modifiés et leur utilisation medicale
CN104531812A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US20140010861A1 (en) 2012-04-02 2014-01-09 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015034925A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides circulaires
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
EP3054017A1 (fr) * 2015-02-03 2016-08-10 Johann Wolfgang Goethe-Universität, Frankfurt am Main ARN circulaire pour le diagnostic et traitement de maladies cardiovasculaires
EP3256591A4 (fr) 2015-02-13 2018-08-08 Translate Bio Ma, Inc. Oligonucléotides hybrides et leurs utilisations
US10760131B2 (en) 2015-02-24 2020-09-01 The Adminstrators Of The Tulane Educational Fund Methods of detecting, diagnosing, and treating atherosclerotic plaque rupture
CN106148494A (zh) * 2015-04-08 2016-11-23 中国科学院北京基因组研究所 一种环状rna在结直肠癌生物标志物中的应用
CN106148495A (zh) * 2015-04-08 2016-11-23 中国科学院北京基因组研究所 一种环状rna在结直肠癌生物标志物中的应用
CN106047989A (zh) * 2015-04-08 2016-10-26 中国科学院北京基因组研究所 一种环状rna在结直肠癌检验标志物中的应用
CN105039337B (zh) * 2015-08-31 2017-08-15 安徽农业大学 5′RACE RNA接头序列及用于扩增miRNA剪切后的靶基因cDNA 5′末端的试剂盒
LU92830B1 (en) * 2015-09-15 2017-04-03 Luxembourg Inst Of Health Lih Biomarkers for heart failure
ES2774519T3 (es) * 2015-09-29 2020-07-21 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Un método para diagnosticar una enfermedad mediante la detección de ARNcirc en fluidos corporales
CN105803101A (zh) * 2016-05-20 2016-07-27 上海伯豪生物技术有限公司 检测环状rna表达丰度的探针、基因芯片及方法
CN106138081B (zh) * 2016-08-12 2018-06-22 青岛大学 一种靶向circRNA的药物组合物及其用途
CN106222173B (zh) * 2016-08-12 2020-09-18 青岛大学附属医院 circRNA MNCR在调节心肌细胞坏死和心肌缺血损伤中的作用
CN106222174B (zh) * 2016-08-12 2020-08-04 青岛大学 circRNA CHIF核苷酸在治疗心脏疾病中的用途
CN109504750A (zh) * 2017-07-14 2019-03-22 戴勇 Plc围手术期肝移植患者环状rna差异性表达谱图谱模型及其构建方法和构建***
CN107557474B (zh) * 2017-10-27 2020-05-08 中南大学湘雅医院 胶质瘤诊断标志物circ15:98707562|98708107及应用
CN108624589B (zh) * 2018-04-17 2021-12-17 广州永诺生物科技有限公司 环状RNA circ-ERBB2及其检测试剂与应用
CN108611418A (zh) * 2018-05-10 2018-10-02 山东大学第二医院 一种检测非小细胞肺癌的特异性表达图谱及检测分析***
CN108796086B (zh) * 2018-07-04 2021-07-30 聊城市人民医院 一种环状RNAcircBCBM1及其非诊断性荧光定量检测方法
CN109439747B (zh) * 2018-09-17 2021-07-30 昆明医科大学第一附属医院 一组用于肺癌诊断的circRNA标志物及其应用
CN109136377B (zh) * 2018-09-25 2021-09-28 浙江师范大学 成人t细胞白血病的治疗药物及诊断试剂盒
CN109295221B (zh) * 2018-10-08 2021-07-27 暨南大学 环状rna作为结直肠癌分子标志物的应用
CN109280705A (zh) * 2018-12-11 2019-01-29 宁夏医科大学总医院 一种环状RNA hsa-circ-0044506及其特异性扩增引物和应用
CN109371025A (zh) * 2018-12-11 2019-02-22 宁夏医科大学总医院 一种环状RNA hsa-circ-0044508及其特异性扩增引物和应用
CN110923321B (zh) * 2019-12-26 2022-08-02 广东省人民医院(广东省医学科学院) 一种环状rna检测试剂盒预测三阴性乳腺癌新辅助化疗反应性
CN113549679A (zh) * 2021-07-08 2021-10-26 南京市儿童医院 LncRNA ANRIL在儿童急性淋巴细胞白血病中的临床应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2218784A1 (fr) * 2009-02-04 2010-08-18 Universität Leipzig Vecteur(s) contenant un gène inductible codant un inhibiteur CDK4/CD6 utile pour traiter les troubles neuro-dégénératifs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2218784A1 (fr) * 2009-02-04 2010-08-18 Universität Leipzig Vecteur(s) contenant un gène inductible codant un inhibiteur CDK4/CD6 utile pour traiter les troubles neuro-dégénératifs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHRISTIN E. BURD ET AL.: "Expression of Linear and Novel Circular Forms of an INK4/ARF-Associated Non-Coding RNA Correlates with Atherosclerosis Risk", PLOS GENETICS, vol. 6, no. 12, E1, 2 December 2010 (2010-12-02), pages 1 - 5 *
ERIC PASMANT ET AL.: "Characterization of a Germ-Line Deletion, Including the Entire INK4/ARF Locus, in a Melanoma-Neural System Tumor Family: Identification of ANRIL, an Antisense Noncoding RNA Whose Expression Coclusters with ARF", CANCER RESEARCH, vol. 67, no. 8, 17 April 2007 (2007-04-17), pages 3963 - 3969 *
YAN LIU ET AL.: "INK4/ARF Transcript Expression Is Associated with Chromosome 9p21 Variants Linked to Atherosclerosis", PLOS ONE, vol. 4, no. 4, E50, 3 April 2009 (2009-04-03), pages 1 - 5 *

Also Published As

Publication number Publication date
WO2012050975A2 (fr) 2012-04-19

Similar Documents

Publication Publication Date Title
WO2012050975A3 (fr) Nouvelles molécules d'arn circulaire de mammifère et utilisations associées
PL2089343T3 (pl) Reakcja chemiczna typu click do wytwarzania cząsteczek reporterowych
WO2011079902A3 (fr) Matériaux biologiques et utilisations de ceux-ci
GB201020995D0 (en) Biological materials and uses thereof
WO2009111676A8 (fr) Petites molécules contenant du bore utilisées en tant qu'agents anti-inflammatoires
WO2014028429A3 (fr) Enzymes et polymérases destinées à la synthèse d'arn
WO2012034116A3 (fr) Petites molécules à titre de modulateurs épigénétiques de la déméthylase 1 spécifique de la lysine et méthodes de traitement de troubles
WO2008151170A3 (fr) Procédé de synthèse du rameltéon et ses intermédiaires
WO2013085850A3 (fr) Synthèse stéréosélective totale de la noribogaïne
UA99936C2 (en) Biaryl substituted azabicyclic alkane derivatives
WO2011077099A3 (fr) Procédés de purification de cucurbiturile
WO2010059317A3 (fr) Procédé de séparation
WO2008067423A3 (fr) Procédé d'amélioration de l'introduction d'adn dans des cellules bactériennes
WO2012061502A3 (fr) Polymorphismes génétiques associés à la thrombose veineuse et la réponse à la statine, procédés de détection et utilisations de ceux-ci
WO2011160052A3 (fr) Procédés et compositions associés à des arn-endonucléases spécifiques d'une séquence
WO2008066869A3 (fr) Systèmes et procédés de suivi de l'amplification et du comportement en matière de dissociation de molécules d'adn
WO2011091435A3 (fr) Méthodes de traitement de maladies hépatiques
WO2012017329A8 (fr) Procédé destiné à des événements génomiques ciblés dans des algues
WO2013028334A3 (fr) Utilisation de petites molécules dans des procédés de purification de biomolécules
WO2012136898A3 (fr) Nouvelles cutinases, leur préparation et leurs utilisations
WO2012062753A9 (fr) Procédé et dispositif pour l'isolement et la purification d'acides nucléiques double brin
WO2010148191A3 (fr) Compositions et procédés pour des cyclofructanes en tant qu'agents de séparation
WO2011021177A3 (fr) Compositions et procédés de pronostic et de traitement du cancer de la prostate
WO2011130426A3 (fr) Compositions et procédés de traitement de mélanome
WO2009025761A3 (fr) Procédés pour identifier des souches bactériennes qui produisent de la l-tyrosine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11833115

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11833115

Country of ref document: EP

Kind code of ref document: A2